% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Nov 3, 2011 7:50 AM Flag

    What is the rev potential for the CF drug?

    Of course, until Vertex has drugs that effectively treat most CF patients, this 3 billion figure will not be realized. However, if just half the 2200 patients that can benefit from Kayleideco pay $200,000/year, then the revenue is 1100 X $200,000 = 220 million per year or $1 per share.

93.89+0.68(+0.73%)Jul 22 4:00 PMEDT